Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.

Berger, Garrett K; Gee, Kevin; Votruba, Cassandra; McBride, Ali; Anwer, Faiz

Berger, Garrett K; Gee, Kevin; Votruba, Cassandra; McBride, Ali; Anwer, Faiz.

Afiliación

Berger GK; College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States; Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States. Electronic address: garrettkberger@gmail.com.
Gee K; College of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
Votruba C; College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
McBride A; College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States; Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
Anwer F; Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.

Crit Rev Oncol Hematol ; 113: 8-17, 2017 May.

Article en En | MEDLINE | ID: mdl-28427526

Asunto(s)

Antígeno Ki-1/inmunología; Neoplasias/metabolismo; Antineoplásicos/uso terapéutico; Brentuximab Vedotina; Humanos; Inmunoconjugados/uso terapéutico; Inmunoterapia; Neoplasias/tratamiento farmacológico

Palabras clave

Antibody-drug-conjugate; Brentuximab vedotin; CD30; Ki-1; Non-hematopoetic; Non-lymphomatous; Solid tumor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígeno Ki-1 / Neoplasias Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google